Sunovion announces positive Parkinson's clinical trial progress
Courtesy
Sunovion, which has its headquarters in Marlborough, found positive results in a clinical trial for at treatment of Parkinson's disease.
Sunovion Pharmaceuticals of Marlborough said Monday a clinical trial for a treatment for those with Parkinson's disease has brought positive results.
Sunovion's potential treatment for Parkinson's demonstrated superior efficacy compared to a placebo in helping Parkinson's patients with motor fluctuations. It was well-tolerated by study participants, the company said.
The treatment, Apomorphine sublingual film, is a thin dissolving strip taken orally. Apomorphine is the only molecule approved for such treatment of Parkinson's episodes, but in the United States is only approved as an injection, according to Sunovion.
The film is being developed as a fast-acting treatment to be taken up to five times a day.
Sunovion said results from the study are expected to support its submission of a new-drug application this spring. The Food and Drug Administration has granted a fast-track designation for the treatment because it could treat a serious medical condition not treated by a current medication.
The potential Parkinson's treatment comes to Sunovion as a result of its 2016 acquisition of Cynapsus Therapeutics Inc., a Toronto company developing the drug.
WBJ Web Partners
Most Recent
Most Recent
0 Comments